Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Yanyan Xu\textsuperscript{a,\dagger}, Jingyuan Xiongb,\textsuperscript{y} Xiyang Sun\textsuperscript{c,\ast}, Huile Gao\textsuperscript{a,\ast}

\textsuperscript{a}Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
\textsuperscript{b}Healthy Food Evaluation Research Center, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
\textsuperscript{c}Hongqiao International Institute of Medicine, Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200336, China

Received 1 September 2022; received in revised form 3 October 2022; accepted 17 October 2022

**KEY WORDS**
Cancer immunotherapy; Immunosuppressive tumor microenvironment; Tumor microenvironment normalization; Targeted nanomedicines; Drug delivery; Environment-responsive nanoparticles; Combinational therapy; Tumor treatment

**Abstract** Cancer immunotherapy has significantly flourished and revolutionized the limited conventional tumor therapies, on account of its good safety and long-term memory ability. Discouragingly, low patient response rates and potential immune-related side effects make it rather challenging to literally bring immunotherapy from bench to bedside. However, it has become evident that, although the immunosuppressive tumor microenvironment (TME) plays a pivotal role in facilitating tumor progression and metastasis, it also provides various potential targets for remodeling the immunosuppressive TME, which can consequently bolster the effectiveness of antitumor response and tumor suppression. Additionally, the particular characteristics of TME, in turn, can be exploited as avenues for designing diverse precise targeting nanomedicines. In general, it is of urgent necessity to deliver nanomedicines for remodeling the immunosuppressive TME and thereby improving the therapeutic outcomes and clinical translation prospects of immunotherapy. Herein, we will illustrate several formation mechanisms of immunosuppressive TME. More importantly, a variety of strategies concerning remodeling immunosuppressive TME and...
strengthening patients’ immune systems, will be reviewed. Ultimately, we will discuss the existing obstacles and future perspectives in the development of antitumor immunotherapy. Hopefully, the thriving bloom of immunotherapy will bring vibrancy to further exploration of comprehensive cancer treatment.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Anticancer immunotherapy, which has been confirmed effective in clinical trials, presents a promising cancer regimen compared with conventional chemotherapy and radiotherapy. Initially, the approval of recombinant versions of the cytokine interferon-α ushered in an era full of innovation and possibility for oncology treatment in 1986. Then the following decades witnessed numerous advances and setbacks during the development of immunotherapy, especially the emergence of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapies, which were highlighted as milestones for cancer immunotherapy despite nonnegligible adverse effects. To date, dozens of cancer immunotherapies, such as durvalumab, tisagenlecleucel, and axicabtagene ciloleucel, have been approved by the medical products administration.

The last 40 years of immuno-oncology research have firmly proved that the innate immune system is of great effect for specifically recognizing, destroying, and memorizing tumor cells without side effects to normal tissue, which is termed cancer immunosurveillance. But the immune system was found to be a double-edged sword in carcinogenesis. It does suppress tumor growth, but it also plays a critical role in promoting tumor progression and metastasis by supporting chronic inflammation, shaping tumor immunogenicity, and restraining antitumor immunity. More specifically, the immunologic sculpting of the immune system leads to the elimination of high immunogenicity clones and the development of multiple immune evasion mechanisms, which subvert the normal immune regulation and ultimately form an immunosuppressive tumor microenvironment (TME).

The above-mentioned phenomenon is accurately described as “cancer immuno-editing”, which conduces to unsatisfactory therapeutic outcomes of clinical treatment. In addition, the tumor immune heterogeneity also obstructs the universal application and effectiveness of immunotherapy. Therefore, there is an urgent need to develop strategies targeting diverse tumor escape mechanisms and reversing the immunosuppressive TME for enhanced immunotherapy.

Primary tumors consist of cancerous cells and stromal cells, such as lymphatic cells, endothelial cells, fibroblasts, and various bone marrow-derived cells (BMDCs), which include tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), mesenchymal stem cells (MSCs), and dendritic cells (DCs), etc. It is well demonstrated that the stroma is a crucial participant in tumorogenesis, cancer growth, metastasis, and therapy resistance. Moreover, adaptive immunoediting greatly alters the original signaling pathways of cancer cells and stromal cells, endowing them with more powerful resistance to immunotherapies. With a further understanding of oncology, remodeling the immunosuppressive TME as well as restoring antitumor immunity has emerged as an essential part of cancer immunotherapies. Among these, rehabilitating immune recognition, decreasing immunosuppression-associated cytokines, modulating immunosuppressive cells, and impeding inhibitory co-stimulatory molecule-related pathways, are intensively studied.

Of equal importance, a variety of nanoparticles (NPs) have been developed for precise and timely delivery of immunotherapies. Nanocarriers can not only shelter the therapeutic cargoes and improve the pharmacokinetics and bioavailability, but also possess the enhanced permeability and retention (EPR) effect to achieve passive accumulation in the tumor region. Furthermore, targeting moieties (i.e., monoclonal antibodies, antibody fragments, peptides, growth factors, etc.) can be decorated to NPs to accomplish active targeting, thereby reducing non-specificity and increasing uptake. More significantly, NPs exhibit several unique advantages: 1) Stimuli-responsiveness to internal TME stimuli (i.e., pH, redox environment, enzymes, and hypoxic, etc.) and external environmental stimulus (i.e., light, heat, ultrasound, and magnetism field, etc.); 2) novel delivery strategies to promote treatment efficiency, such as the shape conversion of NPs, cell-mediated biomimetic NPs, and functional ligand modified NPs; 3) intrinsic properties of different NPs may facilitate in tumor cells killing effects, such as cuproptosis; and 4) feasible implementation of a synergetic combination of multiple therapies.

In this review, we first illustrate the broadly studied formation mechanisms of immunosuppressive TME. Subsequently, we summarize diverse strategies for remodeling the immunosuppressive TME and rewiring host immune responses. We then present the existing obstacles that impede the development and clinical translation of immunotherapy. Ultimately, conclusions and future perspectives on immunotherapy are discussed.

2. Formation mechanisms of immunosuppressive TME

Cancer immunoediting is composed of three phases: elimination, equilibrium, and escape. The immune system eliminates tumor cells through specific recognition of tumor antigens via a series of stepwise events, which is termed the “tumor-immunity cycle”, which basically includes the generation and release of tumor-associated antigens (TAA), the capture and processing of the neoantigens by antigen-presenting cells (APCs), the activation of effector T cells, the TME infiltration of activated tumor-specific T cells through T cell receptor (TCR) and cognate antigen-bound MHC complex, and the eventual recognition of target cancer cells, thereby inducing apoptotic pathways for tumor-killing effects as well as initiating a new round of cancer-immunity cycle. However, if growing tumor cells are not eradicated, cancer tends to enter the equilibrium phase. Then under the impact of immunologic sculpting, one or more steps in the tumor-immunity cycle might be blocked and become dysfunctional, along with...
other factors that contribute to the establishment of immunosuppressive TME, resulting in the tumor escape. The following sections will introduce the most acknowledged formation mechanisms of immunosuppressive TME, which are the key elements of cancer immuno-resistance (Fig. 2). Of note, TME and the immune system are of great intricacy, so each mechanism described below is not separate and independent. Instead, all of the mechanisms interact mutually and thus form the dynamic immunosuppressive TME.

2.1. Reduction of immune recognition

In terms of cancer cells, they are of great genome instability, generating random gene mutations or metabolite variations, some of which support tumor progression and develop resistance to tumor therapies. During the equilibrium phase, tumor cell variants that survived the elimination process are deemed to be in a state of functional dormancy, which may last for years and even decades. The progression of tumors is constrained. At the

**Figure 1** Main strategies for remodeling immunosuppressive tumor microenvironment. The focus is on current advances in tumor targeting nanomedicines for enhanced cancer immunotherapy.

**Figure 2** Main formation mechanisms of the immunosuppressive TME, serving as potential targets for TME remodeling-based antitumor immunotherapy.
same time, the Darwinian selection destroys many original vari-
ants except those that exert higher resistance to immune attack. Then the accumulation of tumor cell variants with dampened immunogenicity or attenuated immune response sensitivity will proliferate and lead the tumor to escape phase, thus indicating the formation of clinically apparent malignant tumor.

Loss of major histocompatibility complex/human leukocyte antigen class I (MHC/HLA I) is one of the mechanisms that account for immunogenicity attenuation. The MHC/HLA I is a membrane-bound protein complex that presents the antigenic information on the surface of tumor cells, which can be specifically recognized by cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs), thereby triggering cancer cell lysis. However, to avoid the control and elimination by CD8+ T lymphocytes, genetically unstable cancer cells are likely to downregulate or shut down MHC/HLA I antigen presentation through transcriptional regulation, post-transcriptional/pre-translational regulation, post-translational regulation, or/and altered signaling mechanisms and extrinsic stimuli from the TME, which has no adverse impact on tumor viability or growth. Intriguingly, natural killer (NK) cells, the second line of defense against lesions, can detect and kill abnormal-MHC/HLA I low cells via killer-cell inhibitory receptors (KIR). But cancers can dodge NK cell-mediated elimination by expressing non-classical MHC/HLA I molecules HLA-G and HLA-E, not to mention the hurdles posed by TME for NK cells to infiltrate into MHC/HLA I negative tumors. Together, immunosurveillance is hampered. MHC/HLA I loss is commonly seen in cancers and responsible for unsatisfactory clinical outcomes, because it not only enables cancers to escape immune destruction, but also endows malignant tumor cells, such as breast cancer, endometrial carcinoma, HPV-associated cervical, and vulvar neoplasia, etc., with resistance to immune checkpoint therapies. However, although a vast diversity of molecular mechanisms are relevant to MHC/HLA I loss and any silence in assembly steps of MHC/HLA I can generate MHC/HLA I loss, certain cancers are considered to share common characterized mechanisms and can be treated precisely. Therefore, much work is required to distinguish different tumor phenotypes. Other alterations, such as loss of antigen processing ability within tumor cells, are also liable for decreased immunogenicity of tumor cells.

DCs are highly specialized APCs, initiating and regulating the innate and adaptive immune responses against tumors, without which the immune recognition would be incomplete. DCs go through maturation when elicited by danger signals released by dying cancer cells, such as damage-associated molecular patterns (DAMPs). Nonetheless, immunosuppressive TME greatly impedes the maturation of DCs in various facets, which is remarkably adverse for antigen presentation, thereby leading to immunological ignorance. Theoretically, the blockade of any participant in the tumor-immunity cycle may lead to the failure of the host defense against cancer.

2.2. Production of immunosuppression-associated cytokines

During tumor development, immunosuppression-associated cytokines that are secreted by cancer cells, stromal cells, and tumor-infiltrating immune cells convolutedly participate in immune reactions and provoke tremendous TME conversion, eliciting immunosuppressive TME that is resistant to cancer immunotherapy.

To meet the requirement for a slew of oxygen and nutrients for tumor progression, pro-angiogenic factors such as vascular endothelial growth factor (VEGF) are overexpressed under the stimulation of many growth factors and hypoxia, leading to the tortuous, disorganized, and inordinately branched vasculature. The vasculature exhibits excessive leakage and higher permeability, then the following elevated interstitial fluid pressure (IFP) and maladjusted lymphatic drainage will make it hard for the entrance of immune cells and nanomedicines. Furthermore, VEGF can downregulate immunity due to its nature of tissue repair. For example, it was certified that VEGF hindered the differentiation of CD34+ hematopoietic stem cells into DCs, weakening the presentation of tumor antigens. Besides, VEGF can also directly suppress T-cell proliferation and considerably lower the cytotoxicity of T cells via VEGFR-2. In addition, it is reported that VEGF stimulation increased the B-cell lymphoma 2 (BCL-2) expression in human microvascular endothelial cells (HMVECs) in a prostate cancer model, and in turn, the up-regulated BCL-2 improved the intratumoral microvascular survival and density as well as tumor growth.

Indoleamine 2,3-dioxygenase (IDO) is an essential enzyme that catalyzes tryptophan degradation, generating an array of immunosuppressive tryptophan metabolites, some of which were verified to be capable of curbing the T cell proliferation in vitro or causing T cell apoptosis. Furthermore, local depletion of tryptophan brings about cellular stress, accordingly inhibiting the mechanistic target of the rapamycin (mTOR) kinase pathway and triggering the kinase activity of general control nonderepressible 2 (GCN2). Thus, the T-cell proliferation is further suppressed, and the naive CD4+ T cells are biased toward differentiation into regulatory T (Treg) cells, thereby resulting in severe immunosuppression.

Transforming growth factor β (TGF-β) produced by various tumor types has dual functions in the advance of tumor. TGF-β acts as a tumor suppressor during the early stage of cancer, inhibiting the cell cycle progression, inducing apoptosis, suppressing growth factor expression, etc., while in the later period, TGF-β promotes angiogenesis, alters cytoskeletal architecture, dysregulates cyclin-dependent kinase inhibitors, etc., which greatly fuel the tumor invasiveness and metastasis. Another cytokine, interleukin-6 (IL-6), can set off signal transducer and activator of transcription 3 (STAT3) and nuclear transcription factor (NF-κB) pathways simultaneously, forming chronic inflammatory TME and propelling the tumor growth, metastasis, anti-apoptosis, etc.

In general, there are a host of cytokines that play an active role in shaping immunosuppressive TME and they collaboratively form a sophisticated interactional net with various cells in TME.

2.3. Infiltration of immunosuppressive cells

The functions of the host immune system are remarkably repressed in cancer patients, mainly on account of reduced homing of immune cells to the tumor tissues as well as enlarged protumor immunosuppressive cell populations. In addition to immuno-modulatory capacity, regulatory immune cells also act as inflammatory cells, contributing to the formation of chronic inflammatory TME and the promotion of immunosuppressive effects.

Treg cell has proven to be a major suppressor at tumor sites, which is defined as adaptive or inducible (i) Treg or Tr1. Unlike forhead box protein 3+ (FOXP3+) naturally occurring (n)
Tregs that prevent the host from autoimmune diseases, the tumor-infiltrating iTregs significantly suppress effector T cells through various mechanisms, generate immunosuppressive cytokines (e.g., TGF-β, IL-10, prostaglandin E2, and adenosine), enhance resistance to apoptosis or anti-cancer therapies\textsuperscript{73}. Several main immunosuppression mechanisms of iTregs lie in 1) The expression of high-affinity IL-2 receptor and extreme dependency on exogenous IL-2, hampering the IL-2 exploitation of conventional T (Tconv) cells and thus resulting in the impediment of Tconv cells activation and proliferation; 2) The constitutive expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), repressing the co-stimulatory signal transmission from APCs to Tconv cells; 3) The secretion of immunosuppressive cytokines and other substances, contributing to the direct death of Tconv cells or APCs, degradation of adenosine triphosphate (ATP) to immunosuppressive adenosine and suppression of most immune cells\textsuperscript{74}.

TAMs also play a prominent role in facilitating the establishment of immunosuppressive TME\textsuperscript{75}. Immature macrophages will differentiate and polarize into different subsets based on the microenvironmental conditions\textsuperscript{76}. There are two main categories, which are proinflammatory classically activated (M1) phenotype and anti-inflammatory alternatively activated (M2) phenotype, respectively\textsuperscript{77}. With the progression of tumors, infiltrating macrophages are increasingly prone to differentiate into M2 phenotype, resulting from the stimulation of enzymes, cytokines, and chemokines in TME\textsuperscript{76,77}. The M2-like TAMs secrete a mass of proangiogenic mediators, proteolytic enzymes, and immunosuppressive cytokines such as IL-10 and TGF-β, assisting the formation of immunosuppressive TME and fostering tumor invasion and migration\textsuperscript{76}. Studies also have demonstrated that the M2-like TAMs promote tumor metastasis by prompting the epithelial-mesenchymal transition (EMT) through the TGF-β/Smad2 signaling pathway\textsuperscript{78,79}. In addition, high TAMs densities are considered to be an indicator of poor prognosis and unfavorable overall survival rates\textsuperscript{80}.

The term “myeloid derived suppressor cells (MDSCs)” was first brought up to describe the heterogeneous cluster of immature myeloid cells in a pathological environment, which consist of mononuclear phagocytes (M-MDSCs) and granulocytes (G-MDSCs or PMN-MDSCs)\textsuperscript{81}. MDSCs stay immature under the influence of multiple factors in TME and are manipulated to become immunosuppressive phenotype, generating ROS and immunosuppressive cytokines (e.g., IL-10, TGF-β)\textsuperscript{82}. It is now well substantiated that MDSCs suppress adaptive antitumor immunity by depressing T-cell activation and function (e.g., T-cell receptor down-regulation, T-cell cell cycle repression, immune checkpoint blockade) and recruiting immunosuppressive cells like Tregs, at the same time, the innate immunity is also restricted by polarizing macrophages to M2-like TAMs and inhibiting the cytotoxicity of NK cells\textsuperscript{82}. Similar to MDSCs, cancer-associated fibroblasts (CAFs) are another core components of immunosuppressive TME. By suppressing and deleting CD8\textsuperscript{+} T cells, inhibiting T cells \textit{via} the CXCL12-CXCR4 axis, reducing the antigens-presenting ability of DCs, secreting CXCL12 and Chitinase-3 like 1 (Chili3)1 to maintain M2-like TAMs, etc., CAFs remarkably support the immunosuppression of TME\textsuperscript{83}. Simply stated, various immunosuppressive cells have significant negative impacts on TME, which, to some extent, contribute to the unsatisfied efficacy of therapeutic outcomes of anticancer immunotherapies.

2.4. Overexpression of inhibitory co-stimulatory molecules

Aside from MHC-presented antigen signal, co-stimulatory molecules on APCs are indispensable for delivering another key signal for T cell activation, without which will cause T cell death or exhaustion (a state of dysfunction)\textsuperscript{84}. The inhibitory co-stimulatory molecules (also known as immunity checkpoint) are intrinsic mechanisms against autoimmune diseases, but tumors malignantly harness the mechanism and upregulate immune checkpoint signals to escape immunosurveillance\textsuperscript{85}. Moreover, the inhibitory signals are greatly associated with altered TME. For example, once the inhibitory co-stimulatory ligands on tumor cells bind to receptors, the metabolic phenotype of T cells will be shifted from glycolysis to fatty acid oxidation (FAO), thus blunting the metabolic processes for activating effector function as well as stabilizing immunosuppressive Treg cells\textsuperscript{85}. Moreover, the expression of inhibitory co-stimulatory receptors will also be upregulated in exhausted T cells, thereby further depressing the function of effector T cells (Teffs)\textsuperscript{85}.

CTLA-4 is expressed mainly in Teffs, which competitively binds to CD80/CD86 on the APCs with CD28, inhibiting the production of IL-2 and the activation of T cells\textsuperscript{86}. Simultaneously, CTLA-4 induces IDO\textsuperscript{86}. Nonetheless, FDA-approved anti-CTLA-4 antibodies are proven to be inadequate for cancer immunotherapy, with inferior efficacy and high toxicity\textsuperscript{87}. Programmed death receptor-1 (PD-1) is expressed on the surface of many TILs, while its ligands, PD-L1, and PD-L2, are mainly overexpressed in many solid tumors and hematologic malignancies\textsuperscript{88}. When engaged with PD-L1 or PD-L2, PD-1 is phosphorylated at tyrosine residues, with the recruitment of Src homology 2 (SH2) domain-containing tyrosine phosphatase 2 and the dephosphorylation of the proximal TCR signaling molecules, thereby leading to the inhibition of T-cell activation, survival, and cytolytic function as well as the promotion to cancer growth\textsuperscript{89,90}. In comparison with CTLA-4, the blockade of the PD-1/PD-L1 pathway has captured more attention due to its lower rates of immunotherapy-related adverse events and better cancer immunotherapeutic effect in clinical trials\textsuperscript{87}. Similarly, T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) bind to galectin-9 and the adhesion molecule carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), triggering the release of BAT3, the suppression of tyrosine kinase LCK recruitment and eventually the anergy or apoptosis of CD8\textsuperscript{+} T cells\textsuperscript{91}. Lymphocyte activation gene-3 (LAG-3) (LAG-3), the inhibitory co-stimulatory receptor of MHC-I, inhibits Teffs via the KIEELE motif, enabling Treg cell-mediated immunosuppression\textsuperscript{92}. LAG-3 is recognized to have synergistic effects with PD-1 in the tumor immune escape, making it effective for co-blocking LAG-3 and PD-1 in cancer treatments\textsuperscript{93}. Despite the prospects of ICIs, it has been noted that there exists cross-regulation between multiple checkpoint molecules\textsuperscript{94}. For example, the co-blockade of PD-1 and PD-L1 led to the upregulation of TIM-3 and LAG-3 on CD4\textsuperscript{+}CD25\textsuperscript{-} T cells and CD4\textsuperscript{+}CD25\textsuperscript{*}Fox3O3 Helios\textsuperscript{+} Tregs in triple-negative breast cancer\textsuperscript{95}. Likewise, the combination of TIM-3 and PD-1 mAbs also increased the expression of LAG-3 and GITR (a co-stimulatory receptor) in TILs\textsuperscript{94}. For the past decade, combining ICIs with other therapeutics, such as chemotherapeutics\textsuperscript{96} and antiangiogenic agents\textsuperscript{97}, has drawn fierce attention and has been broadly investigated both in preclinical testing and clinical trials.

Additionally, glyco-immune checkpoints are under extensive exploration. Aberrant glycosylation is a universal hallmark of
cancer cells, commonly characterized by anomalous expression and glycosylation of mucins, abnormal branching of N-glycans, and increased expression of sialoglycans on proteins and lipids. Sialic acid-binding immunoglobulin-like lectins (Siglec) expressed on most immune cells are receptors for tumor-cell-derived sialoglycans, and the signaling through the sialoglycan-Siglec axis is similar to the PD-1/PD-L1 signaling, which stifles the anti-tumor immunity and brings about immunosuppressive TME. Hitherto few targeted nanomedicines interfering with the sialoglycan-Siglec immune checkpoint have been brought up, it is a potential approach for enhancing cancer immunotherapy.

3. Strategies for remodeling immunosuppressive TME

The immunosuppressive TME, which is shaped under the cooperative effect of tumor cells with poor immunogenicity and various immune cells, dramatically retards the response rates of immunotherapies (e.g., CAR T-cell therapies and ICIs) in recent clinical investigations. Apart from seeking predictive therapeutic biomarkers, rejuvenating the immunosuppressive TME and rehabilitating patients’ inherent immunological systems have emerged as promising approaches in the evolving field of immunotherapy. Inspiringly, abnormalities also represent potential therapeutic targets. Nanomedicine is deemed a potent therapeutic strategy, attributed to its design flexibility, ease of decoration, and versatility (e.g., spatiotemporally controlled drug delivery and release, biodegradability, and the ability to overcome drug resistance). Moreover, inspiring insights into the in vivo fate of nanoparticles have also fueled the investigation of nanomedicine-based antitumor immunotherapy. Combining the understanding of the formation mechanisms of immunosuppressive TME with the advantages of nanomedicines, it is of immense promise to develop effective and precise nanomedicines for remodeling immunosuppressive TME and enhancing the efficiency of anticancer immunotherapies. Of note, due to the sophisticated interactive net formed by the intricate immune system and TME, researchers prefer combinatorial therapy for ameliorated feasibility, so the strategies elucidated beneath will be classified based on the main effect of combinatorial therapy.

3.1. Rehabilitating immune recognition

As described above, any impairment of steps in the tumor-immunity cycle will contribute to the failure of cancer eradication by adaptive immunity. Tactics that target rejuvenating the dysfunctional tumor-immunity cycle for remodeling the immunosuppressive TME have continuously emerged, especially immunogenic cell death (ICD). Under the enormous cellular stress provoked by antitumor therapy, ICD is induced, which encompasses the release of TAAs, DAMPs as well as inflammatory cytokines and the activation of tumor-specific immune responses, thus addressing the poor immunogenicity of edited tumors and eliminating tumors by both anticancer drugs and antitumor immunity. There is a wide range of nanomedicine-mediated ICD triggering approaches. Potent approaches, such as chemotherapeutics (e.g., doxorubicin, paclitaxel, 7-ethyl-10-hydroxycamptothecin), photothermal therapy (PTT), photodynamic therapy (PDT), and oxidative stress amplifiers, have been intensively applied. In the work of Ding et al., reactive oxygen species (ROS)-sensitive nanoparticles loaded with copper chaperone inhibitor DC_AC50 and cisplatin(IV) prodrug were fabricated. Along with the chemotherapeutic effect of cisplatin, massive ROS generated from DC_AC50 spurred on synergistic ICD, thereby restoring the cancer immunogenicity. Chen et al. put forward GSH-depleting second near-infrared (NIR-II) photothermal and photoacoustic agents (denoted as TTF-F4TCNQ) based on the small molecular organic metal adjuvants (OMAs), contributing to elevating immune responsiveness by the ICD effect elicited by PTT and ROS. With the optimized combination of commercially available donors and acceptors, TTF-F4TCNQ exhibited advanced efficiencies, such as broader substrate scope, higher accessibility, and flexibly tuned optical characteristics. Moreover, TTF-F4TCNQ possessed the ability to deplete GSH and cysteine, thus interrupting intracellular redox homeostasis as well as augmenting ROS accumulation. The multifunctional TTF-F4TCNQ had a synergistic impact on arousing abundant ICD and enhancing immune responses to eradicate cancer cells. In addition, the administration of PD-1 antibody assisted the antitumor immunotherapy via increasing T cell infiltrations. Together, both the primary and distant tumors were inhibited in 4T1 tumor-bearing mice due to the suppressed tumor immune evasion and enhanced immune responses (Fig. 3).

Nonetheless, ICD-induced TAAs themselves are not sufficient to elicit potent antitumor immunity owing in large part to the lack of activated APCs, which are responsible for taking in the cancer neoantigens and cross-presenting them to prime naive CD4+ and CD8+ T cells, thereby triggering immunogenic T helper 1 (Th1) and cytotoxic T lymphocyte (CTL) responses. Hence, effective activation of APCs is a prerequisite for TAAs to trigger the tumor-immunity cycle. For DC maturation, various methods have been brought up, such as nucleic acid-based vaccine, calciretinucin, and toll-like receptor (TLR) agonists, which all manifest great prospects. Moreover, Liu et al. proposed that Ca2+-assisted surface polydopamine engineering of DC could effectively relieve the suppressed state and promote DC maturation under 808 nm laser irradiation, offering a potential approach for the elevation of antigen presentation. Furthermore, artificial APCs (aAPCs) have emerged as a powerful alternative to natural APCs, indirectly overcoming the difficulty that APCs are suppressed in TME. Xu et al. developed biomimetic nano-aggregates of aggregation-induced emission photosensitizers (AIEgens) coated with DC cell membranes (DC@AIEdots). Leveraging DC cell membranes, the nano-photosensitizers were capable of crossing the biological barrier of blood vessels to accumulate around the tumor by hitchhiking on T cells, and then artificially presenting antigens to mediate T cell proliferation and activation. AIE photosensitizers could specifically target lipid droplets accumulated in cancer cells, without interference with surrounding immune cells in complex TME. Among a series of synthesized AIE photosensitizers, McTIND-4 was selected for its longest NIT emission and highest ROS generation. The levels of tumor necrosis factor (TNF-α) and interferon (IFN-γ) in DC@AIEdots-treated T cells were 14-fold and 11-fold superior to cells treated with PBS buffer or bare AIEdots. T cell numbers in DC@AIEdots-treated groups were also increased by more than five times, in comparison to the control groups. In vivo experiments also exhibited abundant activated T cell infiltration, apparent tumor size reduction, and distant tumor inhibition, with long-term effects and biocompatibility (Fig. 4).
3.2. Decreasing immunosuppression-associated cytokines

In terms of previous illustrated mechanisms, decreasing the expression or/and the secretion of immunosuppression-associated cytokines is of great prospect for immunosuppressive TME reversal. Among these, VEGF, IDO, TGF-β, and IL-6 have been the most investigated. Song et al. 134 introduced a dual pH-responsive nanocarrier for the co-delivery of VEGF siRNA (siVEGF) and placental growth factor (a homolog of VEGF) siRNA (siPIGF) to breast cancer cells and M2-like TAMs. Based on the ionic gelation between a cationic polyethylene glycol (PEG) and mannose modified-trimethyl chitosan conjugate (PEGₜₐMT) and an anionic poly-(allylamine hydrochloride)-citraconic anhydride (PAH-Cit, PC), PEGₜₐMT/PC/siVEGF/siPIGF NPs were formed. Interestingly, the NPs underwent two stages to overcome biological barriers and achieve on-demand release. First, the benzamide bond between PEG and MT cleaved upon arriving at weakly acidic tumor sites (pH 6.0–7.0), leading to the exposure of mannose ligands and positively-charged groups, which accelerated the active uptake by mannose receptors-overexpressed M2-like TAMs as well as passive uptake by negatively charged tumor cells. Second, a more acidic endosomal or lysosomal environment (pH 4.5–5.5) led to PC hydrolyzation, contributing to charge reversal, endosomal/lysosomal escape, and cytoplasmic release of siRNA. As a result of silencing immunosuppressive VEGF, the combinatorial therapy not only inhibited the proliferation of breast cancer cells but also re-educated M2-TAMs to proinflammatory M1 phenotypes, sharing a synergistic effect on TME remodeling and immunotherapy sensitization.

Recently, two monoclonal antibodies (i.e., anti-VEGF-A antibody Bevacizumab and anti-VEGFR2 antibody Ramucizumab) have been approved for clinical application135. However, some concerns are raised that VEGFR-2 inhibitors may interfere with other receptors of the tyrosine kinase family, on account of structural resemblance136. Modi et al.136 took advantage of structure-based drug design (SBDD) approaches (i.e., docking and molecular

![Figure 3](image-url)
For IDO, recent efforts unveiled many synergetic treatments in combination with IDO inhibitors (e.g., 1-methyl-D-tryptophan (1-MT)\textsuperscript{137–139}, NLG919\textsuperscript{140}, Epacadostat\textsuperscript{141}) and other therapeutic modalities, such as chemotherapy, PDT, PTT and radiotherapy, which all demonstrated relieved immune suppression and enhanced therapeutic effects, offering vast clinical prospects. Our group\textsuperscript{142} designed laser-responsive and size-changeable NPs [(C/I)BP@B-A(D)&M\textsubscript{1m}] decorated with M1-macrophage membranes. M1-macrophage membranes enabled delayed mononuclear phagocyte system clearance and tumor-homing effect via membrane proteins. The NPs were comprised of PEGylated bilirubin with hydrophobic Ce6 and IDO inhibitor indoximode (IND) co-loaded [(C/I)BP] and DOX-embedded and BSA-protected gold nanoclusters [B-A(D)], which could be disrupted in response to laser irradiation. Then the (C/I)BP would reaggregate into “Caterpillar-like” NPs to facilitate retention and sustained drug release, and the small-sized B-A(D) would penetrate into the deep tumor region, thereby reinforcing cytotoxicity. The combination of chemotherapeutic drug, PDT therapy, and reversing tumor immunosuppression by IDO1 pathway exerted great suppression of primary tumor growth and metastasis (Fig. 5). To further bolster the specificity of the nanomedicine, our group fabricated shape-transformable nanomicelles (Ce6/BR-FFVLK-PEG) with macrophage membrane to co-deliver thio-ketal-linked paclitaxel dimer and disulfide-linked 1-MT dimer (denoted as I-P@NPs@M)\textsuperscript{143}. Upon laser irradiation, the spherical nanomicelles turned into nanofibers when stimulated by massive ROS generated by Ce6, thus bolstering retention and cellular internalization in tumor\textsuperscript{144}. With nanomicelles being destroyed, the drug dimers loaded in the hydrophobic core were consequently released and activated to monomeric drugs by ROS and GSH, respectively. Notably, 1-MT blocked the IDO pathway to reduce immune inhibition, thus amplifying ICD triggered by PDT and chemotherapy and synergistically suppressing both \textit{in situ} breast cancer and lung metastasis (Fig. 6). Additionally, researchers have been engaged in discovering potent and safe IDO inhibitors that derived from small-molecule compounds by virtual screening and kinetic method for enzymatic analysis\textsuperscript{145}. Scientists found lead compounds that exerted potential IDO inhibitory activity from PQAs (the natural alkaloids in \textit{Picrasma quassioides}), which were verified more potent than 1-MT, thereby enriching the diversity and availability of natural anti-tumor agents\textsuperscript{145}. As for TGF-\textbeta, it has been authenticated to be a critical promoter of epithelial-mesenchymal transition (EMT), which allows the metastasis of cancer\textsuperscript{146}. Guo et al.\textsuperscript{147} constructed a fucoidan-functionalized DOX-loaded micelle (FD/DOX) to reestablish TME and achieve potent antitumor immune responses for metastatic cancer treatment. Fucoidan, a highly sulfated polysaccharide, had a nanomolar affinity for P-selectin, which supported the hypothesis that fucoidan-functionalized micelle can track tumor cells precisely by hitchhiking on activated platelet. More importantly, fucoidan not only inhibited TGF-\textbeta in the liver fibrosis model but also displayed immunostimulatory function to boost adaptive immune responses, thus having the potential to reverse the immunosuppressive TME. Attribution to the addition of chemotherapy, the micelle was expected to exhibit more potent anti-cancer efficacy. The therapeutic effects of FD/DOX were successfully observed in both \textit{in vitro} and \textit{in vivo} experiments.
Figure 5  Phagocyte-membrane-coated and laser-responsive NPs for combinatorial therapy of chemotherapeutics, PDT and immunosuppression modulation. (A) Preparation process of (C/I)BP@B-A(D)&M1m. (B) Schematic illustration of (C/I)BP@B-A(D)&M1m + laser treatment. (C) Analysis of immune cells in the B16F10-tumor-bearing mice and (D) 4T1-tumor-bearing mice treated with various NPs. (E) Survival curve of the 4T1-bearing mouse models after removing primary tumors by treatment or surgery. (F) Number of lung metastatic foci determined grossly. Treatment groups: 1, PBS; 2, IND; 3, DOX/Ce6 + laser; 4, DOX/Ce6/IND + laser; 5, (C/I)BP + laser; 6, (C/I)BP@B-A(D); 7, (C/I)BP@B-A(D) + laser; 8, (C/I)BP@B-A(D)&M1m + Laser. *P values were calculated by two-tailed Student’s t-test (C, D and F) and one-way ANOVA test (C and D). Data are presented as mean ± SD (n ≥ 3), *P < 0.05, **P < 0.01, and ***P < 0.001 vs. indicated. Reproduced with the permission from Ref. 142. Copyright © 2020, Elsevier Ltd.
thus providing a simple but valuable paradigm of cancer treatment. Other approaches aiming at TGF-β inhibition were also brought up, such as BIX0218948.

3.3. Modulating immunosuppressive cells

3.3.1. Regulatory T cells

It is universally acknowledged that immunosuppressive Treg cells have to be depleted or attenuated, or else immunological treatments such as vaccination and checkpoint blockade will be disabled74. Maneuvers for selectively targeting Treg cells can be divided into three categories, including depletion of effector Treg cells in tumor sites, agonistic antibody affecting Treg suppression, and small molecular inhibitors for Treg depletion or modulation. When it comes to depleting effector Treg cells in tumor tissues, CCR4 is a representative target, which is the receptor for chemokines CCL22 and CCL17 that mainly from DCs and macrophages149. The interaction is crucial for Treg migration and metastasis of CCR4+ lymphoma cells, which simultaneously provides an ideal target for blockade149. But current researches are mostly concentrated on the development of novel anti-CCR4 antibodies rather than targeted nanomedicines, which, therefore, will not be covered in this review. Glucocorticoid-induced TNFR-related gene (GITR) is expressed by Treg cells, acting as a potential target for suppressing Treg150. Sun et al.151 developed an immunomodulating nanosystem based on the combination of phototherapy and immunotherapy, which was denoted as PDA-ICG@CAT-DTA-1. Catalase (CAT) and anti-GITR antibody (DTA-1) were co-loaded to nanoparticles comprised of photothermal agent polydopamine (PDA) and photosensitizer.

Figure 6  Macrophage-mimic and shape-transformable NPs for multimodal breast cancer therapy. (A) Schematic illustration of the construction of I-P@NPs@M. (B) Schematic illustration of anticancer functions of I-P@NPs@M. (C) The DLS measurements and TEM images of I-P@NPs@M and (D) I-P@NPs@M + laser (scale = 50 nm). (E) The tumor volume of in situ tumors in different treatment groups. Reproduced with the permission from Ref. 143. Copyright © 2020, Elsevier B.V.
indocyanine green (ICG). With the aid of the EPR effect, the FDA-ICG@CAT-DTA-1 tended to accumulate in cancer regions and then endocytosed via the vesicle transport pathway by tumor cells. It was worth noting that the nanosystem offered a Treg targeting vehicle for DTA-1, which facilitated the abrogation of tumor immune suppression and the effects of ICD induced by phototherapy, thereby fostering antitumor immunotherapy. ICG@CAT-DTA-1 showed potent antitumor effects in mice models, with an inhibition ratio of 95.1% for primary cancers and 68.7% for abscopal cancers, highlighting the great prospects of this versatile nanosystem. As for small molecular inhibitors for Treg depletion or modulation, low-dose cyclophosphamide (CTX) is one of the most broadly utilized agents, which selectively depletes CD4+CD25+ Treg cells.152,153 Yet, the application of CTX is still restricted to its original role of chemotherapeutic, and articles on both Treg inhibiting function and nanomedicines are rare.

### 3.3.2. Tumor-associated macrophages

Reprogramming TAM towards anti-tumoral phenotype, namely M1-like TAMs, is perceived as significantly beneficial in remodeling immunosuppressive TME.15 The approaches can be generally classified into two types, one is re-educating tumor-promoting M2-like TAMs to M1-like TAMs, and the other is directly hindering the formation and survival of M2-like TAMs. In studies from our group154,155, we constructed a furin-responsive aggregated nanoparticle encapsulating DOX and hydroxylchloroquine (HCQ). The HCQ was a typical autophagy inhibitor, which not only diminished the chemo-resistance of tumor cells but also enhanced NF-κB nuclear translocation and activated the NF-κB pathway to reprogram tumor-promoting TAMs to pro-inflammatory M1-like phenotype, thus reversing immunosuppressive TME. He et al.156 fabricated binary-drug liposomes modified with lactoferrin (LF) for targeting immune-inactive colorectal tumor cells and immunosuppressive M2-like TAMs. The drugs capsulated were FDA-approved histone deacetylase inhibitors, such as paclitaxel, calcipotriol (Cal), and named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes.

### 3.3.3. Myeloid-derived suppressor cells

MDSCs not only impede antitumor immunity presented by T cells but also propel angiogenesis and metastasis of cancer, resulting from quantities of both direct and indirect crosstalk with various cells in tumor region.154,155 Wang et al.156 proposed a self-assembled nano-filament system through the conjugation of MDSCs repressor curcumin and a self-assembled peptide FFE-ss-EE (denoted as Nano-Cur) for lung cancer. Given that Cur was verified to have potential inhibitory capacities on MDSCs but was restricted by its poor bioavailability and tumor accumulation, researchers exploited self-assembled peptide-based nano-filaments to improve the loading capacity and retention effect of curcumin.156 At the same time, nano-filaments exert better tumor retention ability than common nanoparticles because different nanoplatform shapes exhibit different properties. Moreover, curcumin was incorporated into the peptide, making it possible for persistent drug release. Under Nano-Cur treatment, dramatical immunosuppressive effects of the number and immnosuppressive function of MDSCs was witnessed both in vitro and in vivo models, indicating an effective approach for lung cancer treatment. Extensive investigations on suppressing immunosuppressive functions and inhibiting the recruitment of MDSCs have yielded various strategies, such as Neobavaisoflavone nanoemulsion167, multilayer polyarginine nanoparticles loaded with chemokine CCL2 and two different RNAi sequencesmodulating the CCAAT/enhancer-binding protein beta (C/EBPβ) pathway.158,169, micellar hypotoxic low molecular weight heparin-tocopherol succinate nanoparticle,169 etc. Additionally, repolarizing MDSCs is another valid avenue. Wu et al.170 introduced a magnetic nanoparticle-based platform with polyethylenimine modification to complement the effect of radiotherapy for glioma therapy, which could manipulate the repolarization of MDSCs to a pro-inflammatory phenotype that was capable of generating a substantial amount of TNF-α and inducible nitric oxide synthase (iNOS) as well as recognizing and attacking glioma cells.

### 3.3.4. Cancer-associated fibroblasts

As the most abundant stromal cells in TME, CAFs secrete a host of regulatory factors and remodel the extracellular matrix (ECM), thus facilitating the formation of the immunosuppressive TME and tumor progression.157 CAFs depletion or inactivation plays a potential role in developing more powerful cancer therapies. Lang et al.158 developed cell-penetrating peptide (CPP, nine-arginine, R9)-based self-assembly nanoparticles loaded with CXCL12 silencing siRNA (siCXCL12), with fibroblast activation protein-α monoclonal antibodies (anti-FAP-α mAb) absorbed on the surface. The nanosystem actively targeted to CAFs via a specific binding effect between anti-FAP-α mAb and FAP-α, then knocked down the expression of the CXCL 12 gene in CAFs, which inhibited the CXCL12-CXCR4 axis and hindered the maintenance of the tumor-promoting phenotype of CAFs. Therefore, the malignantly immunosuppressive TME was reshaped under the influence of the inactivation of CAFs, thereby hampering the tumor growth and migration for orthotopic prostate tumors. However, compared with CAFs inhibition monotherapy, combinatorial therapy may be more sufficient. Li et al.171 integrated PTT with CAFs regulator to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to a quiescent state with increased lipid droplet storage and reduced

---

*Nanomedicines for cancer immunosuppression remodeling* 4337

---

"Reprogramming TAM towards anti-tumoral phenotype, namely M1-like TAMs, is perceived as significantly beneficial in remodeling immunosuppressive TME. The approaches can be generally classified into two types, one is re-educating tumor-promoting M2-like TAMs to M1-like TAMs, and the other is directly hindering the formation and survival of M2-like TAMs. In studies from our group, we constructed a furin-responsive aggregated nanoparticle encapsulating DOX and hydroxylchloroquine (HCQ). The HCQ was a typical autophagy inhibitor, which not only diminished the chemo-resistance of tumor cells but also enhanced NF-κB nuclear translocation and activated the NF-κB pathway to reprogram tumor-promoting TAMs to pro-inflammatory M1-like phenotype, thus reversing immunosuppressive TME. He et al. fabricated binary-drug liposomes modified with lactoferrin (LF) for targeting immune-inactive colorectal tumor cells and immunosuppressive M2-like TAMs. The drugs capsulated were FDA-approved histone deacetylase inhibitors, such as paclitaxel, calcipotriol (Cal), and named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Calcipotriol (Cal) can transcriptionally deactivate CAFs to achieve better therapeutic outcomes. A vitamin-D receptor ligand named Cal..."
expression of fibroblast activation marker α-smooth muscle actin (α-SMA), which was co-loaded with a typical photosensitizer ICG to tumor cell-derived microparticles (denoted as Cal/ICG@MPs), thus forming an innovative tumor-targeted nanosystem with superb stability, high biocompatibility, low immunogenicity, and target-homing capability. With the assistance of Cal, the depressed CAFs and reduced tumor ECM led to the enhanced accumulation and penetration of ICG, thereby igniting a more potent PTT effect. The synergetic therapy can trigger strong systemic antitumor immune responses and long-lasting immunological memory, realizing excellent tumor eradication effect. Similarly, Nicolás-Boluda et al. proposed multifunctional iron oxide nanoparticles decorated with gold nanoparticles (GIONF) as nanoheaters to deplete CAFs for reversing immunosuppressive TME, highlighting a spatiotemporally controlled physical strategy for cholangiocarcinoma treatment. Up to now, many CAFs inactivators have been leveraged to counteract the immunosuppression in TME to a certain degree, such as salvianolic acid B, telmisartan, etc.

3.4. Impeding inhibitory co-stimulatory molecule-related pathways

Cancer cells activate different immune checkpoint pathways to harbor immunosuppressive functions. Among various inhibitory co-stimulatory molecule-associated signaling pathways, the PD-1/PD-L1 pathway has been the most extensively investigated, which will be taken as an example in the succeeding discussion. Prohibiting strategies include blocking monoclonal antibodies (mAbs) against PD-1 or PD-L1, PD-1/PD-L1 inhibitors, genetic ablation of PD-1 or PD-L1 gene, RNA interference, etc.

The past several years have witnessed immense advances in clinical cancer immunotherapy, with approvals of antibodies targeting PD-1/PD-L1 (e.g., nivolumab, pembrolizumab, cemiplimab, atezolizumab, durvalumab, avelumab), which can efficiently rescue T cells from exhaustion and revive immune response against tumor. Aiming to promote the antitumor efficacy of immunomodulatory mAbs, Jiang et al. integrated two types of mAbs targeting effector cells and tumor cells with nanoparticles to construct immunomodulating nano-adaptors (mNAs), which could facilitate the engagement of effector immune cells and tumor cells to bolster cytotoxicity. Intriguingly, rather than chemically immobilizing mAbs onto NPs, which was at high risk of hurting the valency and affinity of antibodies, the researchers employed anti-IgG (Fc specific) antibody (αFc) as an intermediary between NPs and mAbs. Given that αFc was linked to NPs through orientated conjugation and could noncovalently bind mAbs via specific Fc recognition, both the stability and efficacy of the nano-adaptors were guaranteed. The general applicability of the nano-adaptors was proved in multiple murine tumor models, presenting a versatile nano-platform for mAbs-associated treatment. However, anti-PD-1/PD-L1 antibodies also pose many drawbacks, such as a limited responding proportion of patients, innate and/or acquired resistance, and a series of immune-mediated adverse events.

In recent laboratory investigations, plenty of PD-1/PD-L1 inhibitors have been applied. Our group conjugated acidic-sensitive PD-L1 inhibitor Metformin (MET) with Cε6 through matrix metalloproteinase-2 (MMP-2) cleavable peptide (GPLGVRGDK, pepA) to develop MMP-responsive self-delivery nanoparticles. Apart from type 2 diabetes, MET was also reported to be effective in degrading endoplasmic-reticulum-associated PD-L1 to reverse tumor immunosuppression. Moreover, 1,4-phthalaldehyde was introduced to form an acid-sensitive imine bond between MET and pepA, thus achieving a specific release of positive charged MET in the TME (pH 6.8) and facilitating cellular uptake. The dual-sensitive NPs indicated an intelligent and simple cancer treatment paradigm based on PDT and immunotherapy. There are other approaches for inhibiting PD-1 or PD-L1, such as PPA-1, PD-LYSO, and tubemiside-1. Notably, there exist various adaptively compensatory mechanisms that cooperatively contribute to the aggravation of immunosuppressive TME, which will be reviewed later. Intriguingly, with the emergence of diverse promising PD-1/PD-L1 inhibitors, Jin et al. introduced that artificial intelligence can be elegantly exploited to assess PD-1/PD-L1 inhibitors from three perspectives, which are population screening, response prediction, and efficacy evaluation, thereby conveniently facilitating the selection of different PD-1/PD-L1 inhibitors.

For genetic ablation of PD-1 or PD-L1 gene, Deng et al. designed a CRISPR-Cas9 plasmid to specifically knock out Cyclin-dependent kinase 5 (Cdk5) gene to attenuate the PD-L1 expression on tumor cells, with a biodegradable cationic polymer, poly(β-amino esters) (PBAEs) as the carrier (denoted as aPBAE/Cas9-Cdk5). CRISPR-Cas9 genome editing system is characterized by simplicity, highly targeting ability, and great knockout efficiency. Compared with PEI 25K and HP reagent, aPBAE/Cas9-Cdk5 showed higher transfection efficiency in various cell lines. In vivo, both the melanoma and triple-negative breast cancer models exhibited obvious PD-L1 downregulation, with modulated immunosuppressive TME, enhanced antitumor immunity, and suppressed tumor progression. Based on nanotechnology and genome engineering, aPBAE/Cas9-Cdk5 enriched the options of immunotherapy, providing an innovative candidate for antitumor treatment.

Equally, RNA interference plays a promising role in PD-1/PD-L1 checkpoint blockade. Guo et al. employed a PD-L1 small interfering RNA (siRNA) cross-linker and a photosorbide A (PPA) photosensitizer-bearing DNA tetrahedral framework to fabricate a supramolecular nucleic acid nanogel (denoted as siRNA/PPA-NG). PPAs were grafted onto the backbones of four component DNA strands at the phosphorothioate modification sites to obtain water-soluble PPA-DNA conjugates, which would assemble into a DNA tetrahedral framework. Then, a sticky end was introduced at each vertex of the PPA-bearing DNA tetrahedron, enabling the overhangs pre-designed on the siRNA linker. Eventually, two structural units were successfully cross-linked through the sticky end association to form siRNA/PPA-NG, in which the PPAs can homogeneously dissolve in an aqueous solution under the assistance of hydrophilic DNA. In addition, siRNA was deemed more effective than mAb inhibitors because it suppressed immune checkpoint proteins from the intracellular source, permitting a more thorough PD-1/PD-L1 blockade and an enhanced T-cell mediated cancer elimination. The synergetic combination with PDT further augmented antitumor effects, and the nanogel served as a highly desirable co-packaging vehicle, with satisfactory drug loading capability, great siRNA compression efficiency, and biocompatibility. This nanosystem felicitously exemplified the significance of rational design in combining varied therapeutic agents (Fig. 7). Likewise, Kim et al. engineered a polymeric nanoconjugate consisting of siPD-L1-based polyplexes, PEGralted hyaluronic acid and model foreign antigen ovalbumin, which achieved vigorous rejection towards tumor cells, TME reprogramming, and long-term protective immunity.
Despite inspiring breakthroughs made by PD-1/PD-L1 blockade in clinical practice, the therapeutic outcomes of anti-PD-1/PD-L1 antibodies are constrained due to low durable response rates and acquired resistance that results from compensatory mechanisms of immunosuppressive TME. Therefore, antitumor immunotherapies concerning inhibitory co-stimulatory molecule-related pathways are still expected to be explored and optimized.

3.5. Other strategies

Multiple crosstalk between cancer and immune cells collaboratively shapes the intricate immunosuppressive TME. Researchers have been dedicated to probing more strategies concerning TME remodeling, which can be potentially beneficial for antitumor immunotherapies in the clinic. Apart from the typical strategies delineated above, diverse strategies are continuously emerging.

It is noteworthy that, metabolic behaviors of cancer are of distinguishing features compared with healthy, normal tissues. Altered aerobic glycolysis (also known as the “Warburg effect”) not only provides energy, building blocks, and redox potentials for uncontrollable cancer proliferation, but also generates a large amount of lactic acid and ATP and leads to hypoxia. Therefore, with TME homeostasis being severely disrupted, manifold dysfunctions correspondingly facilitate the formation of immunosuppressive TME. For instance, Treg cells can actively absorb lactic acid produced in highly glycolytic TME, resulting in enhanced PD-1 expression in Treg cells, dampened PD-1 expression in Teff cells, and the failure of PD-1 blockade treatment. Tremendous efforts have been devoted to reversing abnormal metabolic behaviors, alleviating the TME burdens, and ameliorating the efficiency of immunotherapy. Ma et al. put forward bio-responsive DOX-based mannose nanogels (DM NGs), with prolonged blood circulation and reinforced tumor accumulation. The inferior bioavailability of chemo-drug was surmounted by conjugating hydroxyl-containing DOX with hydroxyl-containing mannose via GSH-sensitive-SS bond linker. High GSH concentration in the tumor region would trigger the bond.

Figure 7 Photosensitizer and PD-L1 siRNA copackaged nucleic acid nanogel for synergistic cancer photoimmunotherapy. (A) Preparation process of the PPA-DNA conjugates, tailed-PPA-TET and siRNA/PPA-NG. (B) Schematic illustration of the photoimmunotherapy mediated by siRNA/PPA-NG in vivo. (C) Schematic illustration of the intracellular synergistic antitumor effects of siRNA/PPA-NG. (D) CLSM images of cellular uptake behaviors of siRNA/PPA-NG in tumor sections from the mice after intravenously administration (scale bar = 25 μm). (E) Immunohistochemical and Western blot analysis of PD-L1 expression in primary tumors (scale bar = 50 μm). Treatment groups: 1, PBS; 2, PD-L1/PPA-NG; 3, SCR/PPA-NG + laser; 4, PD-L1/PPA-NG + laser. (F) Growth curves, weights and images of the primary tumors and (G) the distant tumors following the indicated treatment. *P values in (F) and (G) were calculated by ANOVA and two-tailed Student’s t-test. Data are presented as mean ± SD, *P < 0.05, **P < 0.01 and ****P < 0.0001 vs. indicated. Reproduced with the permission from Ref. 190. Copyright © 2022, The Authors.
cleavage and the release of drug. Mannose was engulfed by cells through glucose transporter, which could impede glucose uptake of tumor cells, thus interdicting glycolysis, regulating tumor metabolism, and ultimately resulting in the apoptosis of tumor cells\(^{190}\). Accompanied by robust DOX-induced ICD, the DM NGS manifested effective immunosuppressive TME regulating ability and amplified tumor eliminating effects both in vitro and in vivo, offering a promising combinatorial antitumor chemo-immunotherapy. For a more thorough glycolysis interdiction, Zang et al.\(^{197}\) developed a biomimetic nanocarrier with chemotherapeutic paclitaxel and glycolysis inhibitor PFK15 co-loaded. The nanocarrier was endowed with a dual-targeting ability due to the capsulation of hybrid membranes of breast cancer cell membrane (4T1 cell membranes) and activated fibroblast membranes (CAFs-like NIH3T3 cell membranes), eventually yielding enhanced effects of lactate production abatement and chemo-immunotherapy. Besides, in a study from our research group\(^{198}\), morpholine-modified PEGylated bilirubin nanoparticles loaded with Ce6 and diclofenac (Dc) were brought up (denoted as Ce6&Dc@MBNP), with an aim to settle the issue that PDT-induced oxygen consumption and microvascular damage could aggravate hypoxia, aerobic glycolysis, and angiogenesis. Dc, one of the non-steroidal anti-inflammatory drugs (NSAID), was a lactate dehydrogenase A (LDHA) inhibitor and exploited to interfere with lactate secretion, thereby averting hypoxia-induced resistance-glycolysis and angiogenesis\(^{199}\). Aiming to implement deep penetration in tumors, our group combined a self-propelled nanomotor (NM) with hexokinase-2 (HK-2) siRNA to synergistically reconstruct TME\(^{200}\). The NM adsorbed catalase (Cat) and glucose oxidase (GOx) to persistently generate oxygen bubbles in a cascade manner, assisting the nanomedicine to move towards deep tumor to alleviate hypoxia and the lysosome escaping of HK-2 siRNA to efficiently inhibit glycolysis. Particularly, in vivo results demonstrated a preeminent anti-metastasis outcome of commercially available albumin-bound paclitaxel (PTX@HSA) with NM-si pre-treated for TME modulation (Fig. 8). In general, researchers have been opening up more versatile and comprehensive strategies for addressing glycolysis-associated immunosuppression.

Additionally, hypoxic tumors activate the occurrence of an adenosinergic pathway, which emerges as a major immunosuppressive mechanism and simultaneously a prospective novel therapeutic target for cancer therapy\(^{201}\). Abundant ATP may be degraded to increase the adenosine level. Yu et al.\(^{202}\) constructed an ATP-exhausted nanocomplex by the self-assembly of siRNA/PEI complex,imidazole-2-carboxaldehyde (2-ICA) and Zn\(^{2+}\), with electrostatic adsorbed ICG and surface coated RGD-decorated polyactic acid-hyperbranched polyglycol (PLA-HPG-RGD), which not only intervened in tumor energy metabolism to regulate TME but also depleted excessive intracellular ATP and inhibited ATP synthesis, thereby enhancing PTT-induced ICD. Mao et al.\(^{203}\) contrived ROS-responsive nanoparticles loading CD39/CD73 inhibitor ARL and photosensitizer IR700, which combined ATP release from PTT-induced ICD with ATP degradation constraint to realize a durable antitumor immune response. Nucleotide derivatives such as ARL are potent ectonucleotidase inhibitors that hamper intracellular ATP degradation to adenosine, with unsatisfactory pharmacokinetic properties. Thus, boronic acids (BAs) were exploited to form ROS-responsive reversible covalent esters with ARL. More specifically, the ROS-labile nanoparticles were composed of BA-containing cationic polymer poly [2-acryloyl] ethyl (p-boronic acid benzyl) diethylammonium bromide] (PDEAEA-PBA) and IR700-containing lipid polymer 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000]-IRDye 700 (DSPE-PEG\(_{2000}\)-IR700), which can precisely release ARL in response to ROS. Moreover, in addition to endogenous ROS, IR700 also generated ROS upon near-infrared irradiation, accelerating the release of ARL. Mouse tumor models confirmed that these NPs could reprogram the immunogenic landscape in tumors, and ignite tumor-specific T cell responses as well as tumor regression. Notably, immunological effects were also induced in the patient-derived organotypic tumor spheroid model, which vigorously supported the translation potential for clinical treatment. Altogether, a plethora of feasible strategies has emerged to reconstruct the immunosuppressive TME and enhance anticancer immunotherapy.

4. Obstacles encountered in remodeling immunosuppressive TME

Collectively, investigations on antitumor immunotherapy are vigorously thriving, and the significance of remodeling immunosuppressive TME to enhance therapeutic outcomes has been recognized. Nevertheless, due to the extraordinary intricacy of the immune system and oncology, various facets of the intrinsic mechanisms are still waiting to be unraveled. Moreover, limitations (e.g., low response rates, therapy resistance, adverse events) have emerged in the clinical practice of immunotherapy, which greatly constrain the therapeutic benefits to cancer patients. How to elegantly balance the feasibility of clinical translation and the effectiveness of immunotherapies remains to be tackled. The discussion beneath will briefly introduce several obstacles encountered in immunosuppressive TME modulation and its clinical translation.

In order to spur more successes in immunosuppressive TME rejuvenation, it is imperative to recognize multiple adaptively compensatory mechanisms in immunosuppressive TME. For instance, immunotherapy based on immune response enhancement triggers the activation of the adenosinergic pathway in TME, which is a negative feedback mechanism that dampens TME inflammation and bolsters TME immunosuppression\(^{204}\). Likewise, compensatory inhibitory signaling, such as LAG3 and TIM3, is upregulated in the course of PD-1/PD-L1 blockade therapy, hampering the reinvigoration of CD8\(^{+}\) T cells\(^{205}\). For the sake of complete tumor elimination and tumor relapse inhibition, a broader understanding of such latent compensatory mechanisms is required imminently to polish up existing immunotherapies.

Even though targeted nanomedicines do manifest preeminent capabilities of remodeling immunosuppressive TME, challenges also exist, which inevitably stave off the clinical translation of preclinically viable nanomedicines. Firstly, nanoparticles themselves have aroused wide concerns that potential or unexpected toxicity will be detrimental to normal organs and tissues\(^{206}\). Secondly, the lack of detailed understanding of TME and the immune landscape in a certain subset of patients may invalidate the precise delivery of nanomedicine. Moreover, cancer models adopted in preclinical tests cannot ideally simulate and represent the landscape of TME in clinical human cancer patients, thus posing the predicament that preclinically effective and safe nanomedicines received few benefits in the clinical inspection. For
instance, the EPR effect, as a major underlying mechanism for passive targeted nanomedicine-delivery systems, is universally acknowledged and has been extensively leveraged. But EPR effect-motivated accumulation of nanomedicines in transgenic spontaneous cancer models or humans are reckoned invalid or insufficient in comparison with subcutaneous and orthotopic cancer models, which are commonly utilized in most researches, thus provoking efficacy inconsistency between preclinical tests and clinical trials. Additionally, the protein corona formed onto nanoparticles may greatly alter the in vivo distribution of targeted nanomedicines, leading to off-target distribution and high toxicity. Therefore, the disposal of outdated nanomedicine design criteria and balancing clinical feasibility with innovation are crucial for future advancement. In general, for targeted nanomedicines-based immunotherapies, it is of great challenge to be successfully translated from the proof-of-concept stage to clinically available therapeutics. Faced with countless known and unknown obstacles, improving understanding of cancer heterogeneity, adopting more relevant animal models and testing protocols as well as pre-selecting patients that are likely to respond to corresponding therapies, are all effective approaches.

5. Conclusions and prospectives

It is well established that immunosuppressive TME plays a critical role in the resistance to antitumor immunotherapies. Reversing immunosuppression is undoubtedly conducive to the restoration of human immunity, which is a substantial foundation for immunotherapy. As previously mentioned, rehabilitating immune recognition, decreasing immunosuppressive-associated cytokines, modulating immunosuppressive cells, and impeding inhibitory co-stimulatory molecule-related pathways have manifested favorable efficacy for remodeling the immunosuppressive TME. At the same time, the fabrication elasticity of nanomedicines can be well harnessed during the design of specific delivery systems for immunotherapy. Of late, immunotherapies consisting of nanotechnology and immunosuppressive TME reprogramming have yielded considerable invaluable results, presenting multiple potential avenues for clinical practice.

Nevertheless, due to the intricacy and continuous evolvement of TME, massive researches are still required for further understanding of immuno-oncology. Moreover, according to the properties of specific patients and tumors, individualized
immunotherapy should be leveraged to realize the balance between efficacy and side effects. Also, attention should be concentrated on the latent long-term systematic toxicity. Despite the arduousness, we envisage that enhancing anticancer immunotherapy via remodeling immunosuppressive TME by well-designed targeted nanomedicines can address various bottlenecks of tumor therapy in a coordinated manner, thus achieving a new dimension for clinical cancer treatment.

Acknowledgments

This study was supported by National Natural Science Foundation of China (82173762), 111 Project (B18035, China), the Key Research and Development Program of Science and Technology Department of Sichuan Province (2022DJQ0050, 2022YFS0334).

Author contributions

Yanyan Xu and Jingyuan Xiong conceived the review. Yanyan Xu wrote the manuscript and designed the figures. Yanyan Xu, Jingyuan Xiong, Xiyang Sun, and Huile Gao edited the manuscript. All of the authors have read and approved the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov 2019;18:175–96.
2. Kiae SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, et al. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: new hope for clinical development. Acta Pharm Sin B 2021;11:1083–97.
3. Suda K. Recent advances in cancer immunotherapy. Biomolecules 2021;11:335.
4. Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B 2021;11:1129–47.
5. Al-Salama ZT, Durvalumab: a review in extensive-stage SCLC. Target Oncol 2021;16:857–64.
6. Ali S, Kjeken R, Nederlaender C, Markey G, Saunders TS, Opsata M, et al. The European medicines agency review of Kymriah (Tsigenlecileucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Oncologist 2020;25:e321–7.
7. Papadoulis I, Mueller-Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, et al. EMA review of axicabtagene ciloleucel (yescarta) for the treatment of diffuse large B-cell lymphoma. Oncologist 2020;25:894–902.
8. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. vii6-9 Ann Oncol 2012;23(Suppl 8).
9. Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunooediting. J Clin Invest 2015;125:3338–46.
10. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunooediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–8.
11. Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book 2016;35:298–308.
12. Croci D, Salatino M. Tumor immune escape mechanisms that operate during metastasis. CPB 2011;12:1923–36.
13. Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 2018;15:366–81.
14. Huang J, Yang B, Peng Y, Huang J, Wong SHD, Bian L, et al. Nanomedicine-boosting tumor immunogenicity for enhanced immunotherapy. Adv Fung Mater 2021;31:2011171.
15. Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol 2020;88:106939.
16. Munn DH, Mellor AL. IDO in the Tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol 2016;37:193–207.
17. Melinovicci CS, Boyca AB, Suşman S, Mârginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF)—key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 2018;59:455–67.
18. Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol 2019;10:1835.
19. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 2019;19:369–82.
20. Zhu Y, Yu X, Thamphiwata et SD, Zheng Y, Pang Z. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. Acta Pharm Sin B 2020;10:2054–74.
21. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807–21.
22. O’Neill RE, Cao X. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res 2019;143:145–94.
23. Hu J, Yuan X, Wang F, Gao H, Liu X, Zhang W. The progress and perspective of strategies to improve tumor penetration of nanomedicines. Chin Chem Lett 2021;32:1341–7.
24. Zhang W, Wang F, Hu C, Zhou Y, Gao H, Hu J. The progress and perspective of nanoparticle-enabled tumor metastasis treatment. Acta Pharm Sin B 2020;10:2037–53.
25. Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci (Weinh) 2022;9:e2103836.
26. Muluł TA, Chen Z, Li Y, Xiong K, Jin J, Fu S, et al. Enhancing cancer immunotherapy treatment goals by using nanoparticle delivery system. Int J Nanomedicine 2021;16:2389–404.
27. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015;93:52–79.
28. Xie A, Hanif S, Ouyang J, Tang Z, Kong N, Kim NY, et al. Stimuli-responsive prodrug-based cancer nanomedicine. EBiomed 2020;56:102821.
29. Pérez-Herrero E, Fernández-Medarde A. The reversed intra- and extracellular pH in tumors as a unified strategy to chemotherapy delivery using targeted nanocarriers. Acta Pharm Sin B 2021;11:64–83.
30. Jia W, Wang Y, Liu R, Yu X, Gao H. Shape Transformable Strategies to Improve Tumor Penetration of Nanomedicines. Adv Funct Mater 2020;30:47.
31. Lin C, Tong F, Liu R, Xie R, Lei T, Chen Y, et al. GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy. Acta Pharm Sin B 2020;10:2348–61.
32. Batraovka EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv 2011;8:415–33.
33. Mao Y, Zou C, Jiang Y, Fu D. Erythrocyte-derived drug delivery systems in cancer therapy. Chin Chem Lett 2021;32:990–8.
34. Nguyen VH, Lee BJ. Protein corona: a new approach for nanomedicine design. Int J Nanomedicine 2017;12:3137–51.
35. Song Y, Guo X, Fu J, He B, Wang X, Dai W, et al. Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and...
Nanomedicines for cancer immunosuppression remodeling

in vivo via manipulation of avf3-ligand binding. Acta Pharm Sin B 2020;10:2183–97.

36. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abudrasam M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 2022;375:1254–61.

37. Fan W, Yung B, Huang P, Chen X. Nanotechnology for multimodal synergistic cancer therapy. Chem Rev 2017;117:13566–638.

38. He M, Yang T, Wang Y, Wang M, Chen X, Ding D, et al. Immune checkpoint inhibitor-based strategies for synergistic cancer therapy. Adv Healthe Mater 2021;10:e2002104.

39. Schreiber RD, Old LJ, Smyth MJ. Cancer immunodediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565–70.

40. Ruan S, Huang Y, He M, Gao H. Advanced biomaterials for cell-specific modulation and restore of cancer immunotherapy. Adv Sci (Weinh) 2022;9:e2200027.

41. Gubin MM, Vesely MD. Cancer immunodediting in the era of immuno-oncology. Clin Cancer Res 2022;28:3917–28.

42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.

43. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834–46.

44. Koebel CM, Vermi W, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903–7.

45. Friedman LA, Bullock TN, Sloan EA, Ring KL, Mills AM. MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. Mod Pathol 2021;34:627–36.

46. Lee HJ, Song IH, Park IA, Heo SH, Kim YA, Ahn JH, et al. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and HER2 states, and unaddressed complexity. Cancer Immunol Res 2021;9:1096–8.

47. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion mechanisms, and implications to cancer immunotherapy: tumor antigens and tumor tolerance. Cancer Immunol Res 2020;8:1091–1107.

48. Zajonc DM. Unconventional peptide presentation by classical MHC class I and implications for T and NK cell activation. Int J Mol Sci 2020;21:7561.

49. Aptsiauri N, Ruiz-Cabello F, Garrido F. The transition from HLA-A positive to HLA-A negative primary tumors: the road to escape from T-cell responses. Curr Opin Immunol 2018;51:123–32.

50. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:e218–28.

51. Ramjiawan RR, Griffoen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?. Angiogenesis 2017;20:185–204.
82. Rashid MH, Borin TF, Ara R, Pirani/qho R, Achyut BR, Korkaya H, et al. Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment. *Onco Rep* 2021;45:1171–81.

83. Davidson S, Coles M, Thomas T, Kollias G, Ludewig B, Turley S, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. *Nat Rev Immunol* 2021;21:704–17.

84. Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond evasion. *Adv Exp Med Biol* 2020;1248:201–26.

85. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T, et al. The CD4-related molecule, LAG-3, as a target for improving innate and adaptive anti-cancer immunity. *Expert Opin Ther Targets* 2021;7:839–53.

86. Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. *Cancer Discov* 2020;10:552–67.

87. Bagchi S, Yuan R, Engeleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. *Anna Rev Pathol* 2021;16:223–49.

88. van Houtum EJH, Bull C, Cornelissen LAM, Adema GJ. Sialoglycans and siglecs can shape the tumor immune microenvironment. *Expert Opin Ther Targets* 2019;23:839–53.

89. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T, et al. Tim-3 comes of age as an immunostimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. *Exp Med* 2012;209:1201–17.

90. Li M, Song L, Qin X. Glycan changes: cancer metastasis and anti-tumor immunity. *Expert Opin Ther Targets* 2020;14:3501–16.

91. Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an immune checkpoint for safer and more effective cancer immunotherapy. *ACS Nano* 2018;12:11740–55.

92. Li J, Burgess DJ. Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. *Acta Pharm Sin B* 2020;10:2110–24.

93. Yanyan Xu et al. Self-assembled nanoparticles for cancer therapy. *Front Immunol* 2012;3:860–75.

94. Ahmed M, Tait SWG. Targeting immunogenic cell death in cancer. *Nat Rev Cancer* 2012;12:349–360.

95. Ahmad M, Tait SWG. Targeting immunogenic cell death in cancer. *Nat Rev Cancer* 2021;21:886–902.

96. Zhang Y, Zheng J, Cai J, Qian X, Han J, Zhu X, Zhang Q, et al. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer. *Trends Pharmacol Sci* 2020;41:4–12.

97. Kang J, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. *Curr Top Microbiol Immunol* 2011;350:17–37.

98. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. *J Exp Med* 2012;209:1201–17.

99. Cai J, Qian X, Han J, Zhu X, Zhang Q, et al. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer. *J Cancer Res Clin Oncol* 2019;145:1577–85.

100. Woll Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. *Nat Rev Immunol* 2020;20:173–85.

101. Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. *Eur J Immunol* 2003;33:970–9.

102. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumor immune escape. *Cancer Res* 2012;72:917–27.

103. Yang M, Du W, Li Y, Wu S, He C, Zhai W, et al. Checkpoint molecules coordinately restrain hyperactivated effector T cell in the tumor microenvironment. *Oncoimmunology* 2020;9:170864.

104. Saleh R, Toor SM, Khalaf S, Ellord E. Breast cancer cells and PD-1/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4+ T cells. *Vaccines (Basel)* 2019;7:1149.

105. Galluzzi L, Humeau J, Arpini A, Zitvogel L, Kroemer G. Immunosurveillance with chemotherapy in the era of immune checkpoint inhibitors. *Nat Rev Clin Oncol* 2020;17:725–41.

106. Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. *Front Immunol* 2020;11:1956.

107. Lu M, Song L, Qin X. Glycan changes: cancer metastasis and anti-vaccine cancer. *J Biosci* 2010;35:665–73.

108. Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. *Front Oncol* 2014;4:28.

109. van Houtum EJH, Bull C, Cornelissen LAM, Adema GJ. Siglec signaling in the tumor microenvironment. *Front Immunol* 2021;12:790317.

110. van de Wall S, Santegoets KCM, van Houtum EJH, Bull C, Adema GJ. Sialoglycans and siglecs can shape the tumor immune microenvironment. *Trends Immunol* 2020;41:274–85.

111. Bärenwaldt A, Läubli H. The sialoglycan-Siglec: glyco-immune checkpoint—a target for improving innate and adaptive anti-cancer immunity. *Expert Opin Ther Targets* 2019;23:839–53.

112. Ling Y, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. *Cancer Discov* 2020;10:552–67.

113. Bagchi S, Yuan R, Engeleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. *Anna Rev Pathol* 2021;16:223–49.
124. Ding F, Li F, Tang D, Wang B, Liu J, Mao X, et al. Restoration of the immunogenicity of tumor cells for enhanced cancer therapy via nanoparticle-mediated copper chaperone inhibition. Angew Chem Int Ed Engl 2022;61:e202203546.

125. Chen Y, He P, Jana D, Wang D, Wang M, Yu P, et al. Glutathione-depleting organic metal adjuvants for effective NIR-II photothermal immunotherapy. Adv Mater 2022;34:e2201706.

126. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9:353–63.

127. Chen YL, Chang MC, Chiang YC, Lin HW, Sun NY, Chen CA, et al. Immunomodulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Lett 2018;428:152–63.

128. Lee K, Kim TS, Seo Y, Kim SY, Lee H. The combined hybrid structure of siRNA tagged IVT mRNA (ChriST mRNA) for enhancing DC maturation and subsequent antitumor C T cell immunity. J Control Release 2020;327:225–34.

129. Liu X, Li J, Liu Y, Ding J, Tong Z, Liu Y, et al. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells. Cell Immunol 2016;300:46–53.

130. Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Toll-like receptor (TLR) ligands on maturation of chicken bone marrow-derived dendritic cells. Vet Immunol Immunopathol 2013;155:205–10.

131. Liu Y, Han Y, Dong H, Wei X, Shi D, Li Y. Ca2+-mediated surface polysaccharide engineering to program dendritic cell maturation. ACS Appl Mater Interfaces 2020;12:4163–73.

132. Li X, Deng G, Sun Z, Luo Y, Liu J, Yu X, et al. A biomimetic aggregation-induced emission photosensitizer with antigen-presenting and hitchhiking function for lipid droplet targeted photodynamic immunotherapy. Adv Mater 2021;33:e2102322.

133. Song Y, Tang C, Yin C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials 2018;185:117–32.

134. Gao F, Yang C. Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic. Curr Cancer Drug Targets 2020;20:3–18.

135. Modi SJ, Kulkarni VM. Discovery of VEGFR-2 inhibitors exerting significant antitumor activity against CD44+ and CD133+ tumor stem cells (CSCs): reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur J Med Chem 2020;207:112851.

136. Zhang Y, Jia H, Liu Z, Guo L, Li Y, Li R, et al. D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer. Int Immunopharmacol 2021;101:108203.

137. Li Q, Liu J, Fan H, Shi L, Deng Y, Zhao L, et al. IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment. Biomaterials 2021;269:120388.

138. Liu M, Li Z, Yao W, Zeng X, Wang L, Cheng J, et al. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion. Mol Med Rep 2020;21:445–53.

139. Xing L, Gong JH, Wang Y, Zha Y, Huang ZJ, Zhao J, et al. Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials 2019;206:170–82.

140. Liu Y, Lu Y, Zhu X, Li C, Yan M, Pan J, et al. Tumor microenvironment-responsive prodrug nanoplatof via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy. Biomaterials 2020;242:119933.
161. Yang T, Hu Y, Miao J, Chen J, Liu J, Cheng Y, et al. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. *Acta Pharm Sin B* 2022;12:2658–71.

162. Jiménez-García L, Higuera MÁ, Herranz S, Hernández-López M, Luque A, de las Heras B, et al. A hispanolone-derived diterpenoid inhibits M2-macrophage polarization in vitro via JAK/STAT and attenuates chitin induced inflammation in vivo. *Biochem Pharmacol* 2018;154:373–83.

163. Tang X, Sui D, Liu M, Zhang H, Liu M, Wang S, et al. Targeted delivery of zoledronic acid through the sialic acid–Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages—a promising cancer immunotherapy. *Int J Pharm* 2020;590:119929.

164. Pramanik A, Bhattacharyya S. Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment. *Life Sci* 2022;305:120755.

165. Wang T, Wang J, Jiang H, Ni M, Zou Y, Chen Y, et al. Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments. *Mater Today Bio* 2022;15:100304.

166. Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, et al. The multifaceted role of curcumin in cancer prevention and treatment. *Molecules* 2015;20:2728–69.

167. Ye H, He X, Feng X. Developing neobavaisolactone nanocumulon suppresses lung cancer progression by regulating tumor microenviroment. *Biomed Phamacother* 2020;129:110369.

168. Ledo AM, Sasso MS, Bronte V, Marigo I, Boyd BJ, Garcia-Fuentes M, et al. Co-delivery of RNAi and chemokine by polyarginine nanocapules enables the modulation of myeloid-derived suppressor cells. *J Control Release* 2019;295:60–73.

169. Long Y, Lu Z, Xu S, Li M, Wang X, Zhang Z, et al. Self-delivery micellar nanoparticles prevent premetastatic niche formation by interfering with the early recruitment and vascular destruction of granulocytic myeloid-derived suppressor cells. *Nano Lett* 2020;20:2219–29.

170. Wu C, Muroski ME, Misra J, Lee-Chang C, Shen Y, Rashidi A, et al. Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. *Nanomedicine* 2019;16:126–37.

171. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. *Nat Rev Drug Discov* 2019;18:99–115.

172. Lang J, Zhao X, Qi Y, Zhang Y, Han X, Ding Y, et al. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. *ACS Nano* 2019;13:12357–71.

173. Li X, Yong T, Wei Z, Bie N, Zhang X, Zhan G, et al. Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts. *Nat Commun* 2022;13:2794.

174. Nicolás-Boluda A, Vaquero J, Laurent G, Renault G, Bazzi R, Donnadieu E, et al. Photothermal depletion of cancer-associated fibroblasts normalizes tumor stiffness in desmoplastic cholangiocarcinoma. *ACS Nano* 2020;14:5738–53.

175. Chen Y, Hu M, Wang S, Wang Q, Lu H, Wang F, et al. Nano-delivery of salivancinoid B induces the quiescence of tumor-associated fibroblasts via interfering with TGF-β1/Smad signaling to facilitate chemo- and immunotherapy in desmoplastic tumor. *Int J Pharm* 2022;623:121953.

176. Zhou Q, Zhou Y, Liu X, Shen Y. GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. *Sci Rep* 2017;7:13379.

177. Zhu Y, Fu T, Tan Y, Hong Y, Meng T, Liu Y, et al. Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells. *Theranostics* 2019;9:6764–79.

178. Darvin P, Toor SM, Sasidharan Nair V, Eldor E. Immune checkpoint inhibitors: recent progress and potential biomarkers. *Exp Mol Med* 2018;50:1–11.
hypoxia alleviation and glycolysis inhibition for promoted anti-metastasis. *Acta Pharm Sin B* 2021;11:2924–36.

201. Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. *Nat Rev Cancer* 2017;17:709–24.

202. Yu M, Zeng W, Ouyang Y, Liang S, Yi Y, Hao H, et al. ATP-exhausted nanocomplexes for intratumoral metabolic intervention and photoimmunotherapy. *Biomaterials* 2022;284:121503.

203. Mao C, Yeh S, Fu J, Porosnicu M, Thomas A, Kucera GL, et al. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. *Sci Transl Med* 2022;14:eabh1261.

204. Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors. *Front Cell Dev Biol* 2020;8:672.

205. De Jong WH, Born PJA. Drug delivery and nanoparticles: applications and hazards. *Int J Nanomedicine* 2008;3:133–49.

206. Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?. *J Control Release* 2016;244:108–21.

207. Sun D, Zhou S, Gao W. What went wrong with anticancer nanomedicine design and how to make it right. *ACS Nano* 2020;14:12281–90.

208. Luan X, Yuan H, Song Y, Hu H, Wen B, He M, et al. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. *Biomaterials* 2021;275:120910.

209. Xiao W, Gao H. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system. *Int J Pharm* 2018;552:328–39.

210. Farshbaf M, Valizadeh H, Panahi Y, Fatahi Y, Chen M, Zarebkohan A, et al. The impact of protein corona on the biological behavior of targeting nanomedicines. *Int J Pharm* 2022;614:121458.

211. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. *Adv Drug Deliv Rev* 2017;108:25–38.